Clinical Trial Update: A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL) [Phase 2]

View source ↗

Summary

This update notes the completion of a Phase 2 trial evaluating epigallocatechin-3-gallate (EGCG) for cardiac involvement in light chain (AL) amyloidosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiac Amyloidosis
• Light-chain Amyloidosis

Drugs mentioned

• Epigallocatechin-3-gallate (EGCG) (Epigallocatechin-3-gallate)

Snippet

Sponsor: Florian Michel | Conditions: Light Chain (AL) Amyloidosis, Cardiac Involvement | Phase 2 | Status: COMPLETED